Rodman & Renshaw Starts Imprimis Pharmaceuticals (IMMY) at Buy

November 28, 2016 7:50 AM EST
Get Alerts IMMY Hot Sheet
Price: $2.76 +3.37%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade IMMY Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Rodman & Renshaw initiated coverage on Imprimis Pharmaceuticals (NASDAQ: IMMY) with a Buy rating and a price target of $5.

Analyst Raghuram Selvaraju said, "In our view, Imprimis is intriguing for two reasons: (1) its risk-mitigated approach to product development, based on optimizing formulations of existing approved drug substances as well as developing combination products that meld multiple known active pharmaceutical ingredients (APIs); and (2) its potential to deliver lowercost versions of existing approved therapies. In the United States, sales of ophthalmic drugs could reach over $8B annually within the next 4-5 years. We believe that Imprimis, with its DropLessĀ® and LessDropsĀ® formulations, could gain a substantial foothold in this market. We note that Imprimis has access to a wide array of patent-protected compounding innovations through a network of compounding experts, and has launched products in the urology, otolaryngology and infectious disease arenas."

For an analyst ratings summary and ratings history on Imprimis Pharmaceuticals click here. For more ratings news on Imprimis Pharmaceuticals click here.

Shares of Imprimis Pharmaceuticals closed at $2.61 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Rodman & Renshaw

Add Your Comment